Deutsche Bank lifts target for Redcare Pharmacy stock

Published on 10/05/2026 at 13:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Deutsche Bank lifted its target to EUR 104.00 on September 29, 2026. Redcare Pharmacy stock costs EUR 66.90 after EUR 70.18, down 4.67 percent.

Aquarellmalerei eines niederländischen Logistikstandorts im Abendlicht am Wasser — Redcare Pharmacy (Shop Apoth), ISIN NL0012044747, präsentiert Aquarellgemälde eines niederländischen Logistikstandorts bei Abendlicht, Illustration mit AI erstellt.

Redcare Pharmacy stock (ISIN NL0012044747) was at EUR 66.90 at Lang & Schwarz on October 5, 2026 at 1:13 p.m. CEST, down 4.67 percent from the prior close of EUR 70.18. Deutsche Bank Research raised its target from EUR 103.00 to EUR 104.00 on September 29, 2026, while retaining a Buy rating. The move leaves the target 55.46 percent above the Lang & Schwarz price.

Deutsche Bank target reaches EUR 104

According to finanzen.at on September 29, 2026, analyst Jan Koch cited sustained strength in German prescription medicines and a recovery in non-prescription sales during the third quarter. Deutsche Bank described the confirmed operating-profit margin as conservative.

The target increase followed Redcare Pharmacy's second guidance increase for full-year 2026. It also gives the analyst view a direct operating reference, because the company tied its update to preliminary third-quarter prescription revenue growth of 56.00 percent and September growth of 51.00 percent.

German Rx guidance rises to EUR 760 million

Redcare Pharmacy now expects total revenue growth of 16.00 percent to 18.00 percent in full-year 2026, compared with 15.00 percent to 17.00 percent previously. The German prescription business is projected to generate EUR 730.0 million to EUR 760.0 million, versus EUR 680.0 million to EUR 720.0 million before.

The company kept its non-prescription growth outlook at 10.00 percent to 12.00 percent and its adjusted EBITDA margin range at 2.50 percent to 3.00 percent. The unchanged margin range makes prescription growth the central operating variable in the latest update.

These figures come from the Redcare Pharmacy announcement published through FT.com on September 28, 2026. The full third-quarter interim statement and conference call are scheduled for October 29, 2026, creating the next quantified test for the preliminary growth rates.

Stock falls below prior close

The Lang & Schwarz price of EUR 66.90 is EUR 3.28 below the prior close of EUR 70.18. The decline contrasts with the recent analyst support and places the share 25.75 percent below the 52-week high of EUR 90.10, while remaining EUR 36.70 above the 52-week low of EUR 30.20.

Redcare Pharmacy trades under ticker RDC.DE on Xetra and is included in the SDAX. Market capitalization stood at EUR 1.3 billion as of October 5, 2026, while the primary exchange quote was EUR 66.80 at 1:08 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Redcare Pharmacy stock.